FDA Approves Enhertu for HR+/HER2-low Breast Cancer: Key Trial Results & Insights Breast 3 Mins Read FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in Treatment Published: February 20, 2025 On…
ENHERTU® (Trastuzumab Deruxtecan, T-DXd) Outperforms Chemotherapy in Metastatic Breast Cancer: SABCS 2024 DESTINY-Breast06 Results Breast 2 Mins Read The San Antonio Breast Cancer Symposium (SABCS) 2024 showcased new data from the DESTINY-Breast06 study, examining the efficacy of ENHERTU®…
ASCO 2020: New Developments in the Treatment of Hard to Treat Cancers General 3 Mins Read In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Cristian Massacesi, MD, Senior Vice President, Head of…
